Literature DB >> 510830

Functional studies in patients with the glucagonoma syndrome.

J J Holst, S Helland, S Ingemannson, N B Pedersen, H von Schenck.   

Abstract

Four patients with glucagon-producing tumours of the pancreas were investigated. Fasting plasma glucagon concentrations ranged from 209--625 pmol/l. Plasma insulin concentrations were normal except in one patient, where the tumour also produced insulin (558 pmol/l). Intravenous glucose (25 g/m2) depressed the glucagon concentration in two patients, while no change was noted in the others. Intravenous arginine stimulated glucagon secretion in three patients, but not in the fourth. Intravenous somatostatin suppressed glucagon secretion in all three patients investigated. All patients had abnormally low plasma levels of individual amino acids; glucogenic and branched-chain amino acids were equally depressed. Surgical removal of the tumours led to complete recovery from dermatosis and the glucagon levels were normalized. Postoperative tests were performed in three patients. The alpha-cell responsiveness to iv glucose was restored. Glucose tolerance (Kg-value) was improved in one patient (0.73 to 1.65), persistently low in one patient (0.75 to 0.72) and impaired in the third patient (1.35 to 1.09). It is concluded that none of these functional tests will be of diagnostic value in cases suspected of glucagonomas. The results also show that glucose homeostasis is remarkably unaffected by the extreme hyperglucagonaemia of these patients and that hypoaminoacidaemia is an important consequence of chronic hyperglucagonaemia.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 510830     DOI: 10.1007/bf01219741

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  26 in total

Review 1.  [Glucagon syndrome].

Authors:  J J Holst
Journal:  Ugeskr Laeger       Date:  1975-11-03

2.  Localization of glucagonomas by catheterization of the pancreatic veins and with glucagon assay.

Authors:  S Ingemansson; J Holst; L I Larsson; A Lunderquist
Journal:  Surg Gynecol Obstet       Date:  1977-10

3.  Intravenous glucose tolerance as a tool in definition and diagnosis of diabetes mellitus.

Authors:  K LUNDBAEK
Journal:  Br Med J       Date:  1962-06-02

4.  Production and characterization of an antiserum against pancreatic glucagon.

Authors:  H Von Schenck
Journal:  Clin Chim Acta       Date:  1977-11-01       Impact factor: 3.786

5.  Metabolic studies and glucagon gel filtration pattern before and after surgery in a case of glucagonoma syndrome.

Authors:  H von Schenck; J I Thorell; J Berg; G Bojs; J F Dymling; B Hallengren; O Ljungberg; S Tibblin
Journal:  Acta Med Scand       Date:  1979

6.  Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients.

Authors:  C H Mortimer; W M Tunbridge; D Carr; L Yeomans; T Lind; D H Coy; S R Bloom; A Kastin; C N Mallinson; G M Besser; A V Schally; R Hall
Journal:  Lancet       Date:  1974-04-20       Impact factor: 79.321

7.  Necrolytic migratory erythema with carcinoma of the pancreas.

Authors:  D S Wilkinson
Journal:  Trans St Johns Hosp Dermatol Soc       Date:  1973

8.  A dermatosis specifically associated with a tumour of pancreatic alpha cells.

Authors:  R D Sweet
Journal:  Br J Dermatol       Date:  1974-03       Impact factor: 9.302

9.  An islet cell carcinoma containing glucagon and insulin. Chronic glucagon excess and glucose homeostasis.

Authors:  G Boden; O E Owen; I Rezvani; B I Elfenbein; K E Quickel
Journal:  Diabetes       Date:  1977-02       Impact factor: 9.461

10.  Absence of true pancreatic glucagon but persistence of circulating pancreatic glucagon-like immunoreactivity after pancreatectomy in pigs.

Authors:  J J Holst; M Kreutzfeldt; G Holm; E Jensen; J S Poulsen; B Sparsö; B Sparsö; A Schmidt
Journal:  Diabete Metab       Date:  1978-06
View more
  4 in total

1.  Absence of islet alpha cell function in pancreatectomized patients.

Authors:  A Tiengo; M Bessioud; I Valverde; A Tabbi-Anneni; S Delprato; J Alexandre; R Assan
Journal:  Diabetologia       Date:  1982-01       Impact factor: 10.122

2.  Effect of streptozotocin in a case of glucagon-secreting malignant islets-cell tumor.

Authors:  S Del Prato; A Rovira; P Tessari; A Avogaro; R Nosadini; I Valverde; R Trevisan; A Tiengo
Journal:  J Endocrinol Invest       Date:  1984-04       Impact factor: 4.256

Review 3.  Pancreatic glucagonoma with and without syndrome. Immunocytochemical study of 5 tumour cases and review of the literature.

Authors:  E Ruttman; G Klöppel; G Bommer; M Kiehn; P U Heitz
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1980

4.  Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours.

Authors:  J J Holst
Journal:  Diabetologia       Date:  1983-05       Impact factor: 10.122

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.